InvestmentJun 9, 2026, 09:31 AM
AIM ImmunoTech Raises $2.65M in Direct Offering & Private Placement
AI Summary
AIM ImmunoTech Inc. announced definitive agreements for a registered direct offering and concurrent private placement, aiming to raise approximately $2.65 million in gross proceeds. The offering, priced at-the-market, involves the sale of 2,554,119 shares of common stock in the direct offering and an equal number of unregistered shares (or pre-funded warrants) along with Class J warrants to purchase up to 10,216,476 shares in the private placement, all at $0.5189 per share. The company plans to use the net proceeds for clinical drug supply manufacturing, current and planned Phase 3 clinical trial activities, and working capital.
Key Highlights
- AIM ImmunoTech secured approximately $2.65 million in gross proceeds from the offering.
- The offering includes a registered direct offering and a concurrent private placement.
- 2,554,119 common shares will be sold at $0.5189 per share in the direct offering.
- A concurrent private placement includes 2,554,119 unregistered shares or pre-funded warrants.
- Class J warrants to purchase up to 10,216,476 shares were also issued.
- Warrants have an exercise price of $0.5189 per share and expire in five years.
- Proceeds will fund clinical drug supply, current and planned Phase 3 trials, and working capital.
Price Impact
More from AIM